Abstract
Carbohydrate binding proteins (CBPs) are attractive targets in medicine and biology. Multivalency, with several glycans binding to several binding pockets in the CBP, is important for high-affinity interactions. Herein, we describe a novel platform for design of multivalent carbohydrate cluster ligands by directed evolution, in which serum-stable 2′-fluoro modified RNA (F-RNA) backbones evolve to present the glycan in optimal clusters. We have validated this method by the selection of oligomannose (Man9) glycan clusters from a sequence pool of ~1013 that bind to broadly neutralizing HIV antibody 2G12 with 13 to 36 nM affinities.
Many events in host-pathogen recognition, cell adhesion and cell signaling are mediated by carbohydrate-protein interactions.1 Therefore, the design or discovery of carbohydrate structures that can faithfully mimic or interrupt interactions with carbohydrate binding proteins (CBPs) has potentially broad applications in medicine, including the development of vaccines,2 immunomodulatory agents,3 diagnostics,4 and anti-adhesion drugs against cancer and other diseases.5
Whereas CBPs typically have low affinity (KD ~ mM to μM) for individual glycan units, high affinity interactions are achieved through multivalent interactions with glycan clusters.6 Rather than using rational design and medchem to optimize multivalency to match the target binding sites (Figure 1a), our lab is developing directed evolution methods to rapidly select optimal multivalent glycan clusters from extremely diverse libraries of 1012-1013 structures (Figure 1b). Previously, we have clustered carbohydrates on libraries of DNA aptamer-7 or peptide backbones and developed methods to genetically encode and amplify these libraries.8 RNA has a more diverse structural repertoire than DNA, motivating the display of glycan clusters on RNA backbones.9 Although RNA is highly susceptible to nuclease degradation, 2′-deoxy-2′-fluoro RNA (F-RNA) exhibits increased serum stability.10 Herein, we report a new method for directed evolution of carbohydrate clusters assembled on F-RNA backbones. We demonstrate that this method can evolve tight binders of the HIV antibody 2G12,11 a target with four glycan binding pockets12 that is of interest in HIV vaccine design.2b-d
Figure 1.

Design strategies for carbohydrate cluster ligands. a) Rational design or trial and error typically result in mid μM to high nM binding affinities. b) In our approach, carbohydrate clusters presented on an extremely diverse library of ~1013 modified F-RNA scaffolds are subjected to selection. Sampling this vast structure space yields potentially highly optimized clusters with low nM binding affinities.
Unlike our previously reported SELMA8a (SELection of Modified Aptamers) method, in which glycan-modified DNA was covalently displayed on unmodified DNA,7b, 13 the present method (Capture SELMA) utilizes a capture strategy (Scheme 1), in which a nascent RNA transcript from a DNA template is non-covalently hybridized to a “capture strand”, and thus travels with its DNA template. The DNA template can be amplified by PCR, regardless of subsequent glycosylation of the RNA, without reverse transcription.14 Selection begins with a (-)-strand template (Form A) encoding the random library (25 random bases in red). The capture strand is annealed (Form B), then extended to generate dsDNA library template (Form C). A “capture strand rigidifier” is then hybridized to most of the capture strand (Form D) to prevent secondary structure formation and discourage selection of sequences that depend on hybridizing anywhere other than to the 5′ end (blue). T7 R&DNA polymerase15 and triphosphates are then added to transcribe F-RNA from the template (Form E). The 5′ end of the template strand contains an isodC modified nucleobase (green star) to stall the polymerase and prevent dissociation from the template.16 The nascent F-RNA (Form E, wavy strand) is then captured on a region of complementary sequence at the 5′ end of the capture strand (Form F).
Scheme 1. Library Constructiona.

a a) Architecture of the Capture SELMA construct. b) structure of the Man9 oligomannose glycan. c) Capture SELMA cycle. Translucent colors denote F-RNA and solid colors denote DNA. The stem-loop pictured in the RNA region is illustrative of potentially folded RNA, but library sequences are random in the red N25 region.
Transcription is carried out in the presence of ribopurines but 2′-deoxy-2′-fluoropyrimidines, where uridine is replaced with 2′-deoxy-2′-fluoro(5-ethynyl)uridine, for CuAAC17 attachment of glycan azides.14c, 18 The resulting glycosylated F-RNA library (Form G) then undergoes selection for binding to the target and the bound fraction is amplified by PCR with a biotinylated forward primer (Form H). The biotinylated strand is then removed with streptavidin beads, regenerating Form A of the library to begin the next round of selection.
Several features of the oligonucleotide design were important for optimal library function. First, to avoid early transcript termination in the presence of fluoropyrimidines19, the beginning of the RNA sequence (blue) was designed to contain only natural purine bases. Additionally, this sequence, which must anneal to the capture strand, was designed to avoid formation of G quadruplexes20 or stable secondary folds that could interfere with efficient hybridization of the RNA transcript to the capture strand (see SI Figures 1-4 for gel analyses illustrating library construction).21 A control experiment verified that the captured RNA strand did not significantly exchange with free RNA transcripts in solution (SI Figure 5). A poly(A) spacer (orange) was included to distance the capture annealed region from the random region (red) bearing the glycans. The required ethynyl fluorinated uridine triphosphate (1) was prepared by a brief synthetic sequence (Scheme 2). 1 was readily incorporated by R&D polymerase into the transcription product (SI Figures 1, 3). Denaturing and native polyacrylamide gels exhibited bands of the expected size for each stage of the selection cycle (SI Figures 1, 2).
Scheme 2. Synthesis of 2′-deoxy-2′-fluoro(5-ethynyl)uridine triphosphateb.

bReagents and conditions: (a) 2′-fluoro-2′-deoxyuridine, NIS, DMF, 60°C, 7 h, 82%; (b) Pd(PPh3)2Cl2, CuI, ethynyltri-ethylsilane, ACN, Et3N, 60°C, 1 h, 86%; (c) Proton sponge, (MeO)3PO, POCl3, −20°C, 1 h; then [Bu3NH]2P2O7, Bu3N, DMF, −20°C, 45 m, 22%; (d) TBAF, ACN, rt, 18 h, 91%.
With an optimized protocol in hand for generating the library, we commenced selection for 2G12 binders. For the first round, a 20 pmol library (~1.2 × 1013 library members) was incubated with 150 nM 2G12, and the bound complexes were captured on Protein A magnetic beads. The bead-bound library fraction was eluted by 3.5 M MgCl2 disruption of the antibody/protein-A interaction and quantified by qPCR (Figure 2a). Although successive rounds of selection included more stringent conditions (lower antibody concentration, higher temperature, increased washes, see Figure 2a and SI Table 2), a small parallel selection was run under the original conditions at each round to assess enrichment (Figure 2b). Prior to each selection with target, the library was incubated with empty beads and the supernatant was transferred to another tube to select against bead binders or plastic binders.
Figure 2.

Library fraction bound and clone frequency at each round of selection. a) Percent of library bound under selection con-ditions, quantified by qPCR. b) Control conditions to monitor library fitness: percent bound to constant 150 nM 2G12, quantified by qPCR. c) Clone frequency over final six rounds of selection.
When qPCR indicated increases in library recovery, stringency was increased by lowering the 2G12 target concentration (eventually down to 2 nM), increasing the number of wash cycles and volume for bead-bound library, increasing selection temperature from room temperature to 37 °C, or switching from Protein A to Protein G beads. Recovery increased dramatically in the first eight rounds (Figure 2b) from < 0.1 % to ~10 %. The increase of selection temperature in round 9 and the switch to Protein G beads in round 13 each resulted in temporary decreases in library recovery (Figure 2a), which typically increased again after multiple rounds under the same conditions.
Throughout selection, the number of glycans per library member, as assessed by PAGE of DNAse-digested library (SI Figure 6), narrowed from a broad distribution to 2-4 glycans/clone, and the melting behavior of the library DNA visibly shifted to a higher temperature distribution (SI Figure 7). 36 clones from rounds 13, 15, 17 and 18 were sequenced and their 2G12 binding behavior assessed (Figures 2c, 3). Nitrocellulose filter binding assays22 were conducted with glycosylated F-RNA transcripts, whereas in an alternative assay, clones were produced as glycosylated F-RNA/DNA hybrids (Form G) and qPCR was used to quantify 2G12-bound complexes captured on protein A beads.
Figure 3.

Predicted fold of clones 15F1 and 15F3 and mutant sequences with binding data. a) Filter binding curves (left Y-axis) and qPCR binding curves (right Y-axis) for clones 15F1 and 15F3. b) 15F3 mutant 1 binding (qPCR assay). c) 15F1 RNAFold-predicted structure. Green U = modified uridine, bearing Man9-cyclohexyl-triazole at uridine 5 position. The red asterisk indicates a predicted G-U wobble base pair. X = (A)10 spacer (see SI Table 1). d) 15F3 RNAFold-predicted structure. e) Binding data and sequences. Red = glycosylation sites, cyan = mutated glycosylation sites, yellow = auxiliary mutations that maintain stem stability after glycosylation site mutation. nd = not determined. nb = no binding at 300 nM 2G12. Data were obtained in duplicate. Reported errors are the standard error of the curve fit.
Among the major clones observed in the final rounds, 15F1 and 15F3 became most dominant after rounds 17 and 18. They bound (Figure 3a,e, SI Figure 10) with nanomolar affinity to 2G12 (KDs of 40 ± 6 and 13 ± 2 nM, respectively) in the filter binding assay, and those results agreed well with the qPCR binding assay results (KDs of 40 ± 4 and 19 ± 3 nM, respectively). In the predicted secondary fold (RNAfold)23 of both clones, the reverse primer constant sequence hybridizes with three bases at the 5′-end of the aptamer where one glycan is present, whereas the remaining 2-3 glycans are on a stem-loop feature (Figure 3c, d).
To further understand the structure and glycan-dependency of binding of the two clones that displayed nanomolar binding, we tested single U->X transition or transversion point mutations to remove each possible glycosylation site (three for 15F1 and four for 15F3) while the complementary base in the predicted stem structure was mutated to retain the predicted fold (Figure 3e, SI Tables 3,4). The qPCR binding method was used to test each mutant at 0 nM and 300 nM 2G12 (SI Figure 11, 12). Only 15F3-mutant 1 (“M1”) displayed any binding to 300 nM 2G12, suggesting that three glycosylation sites are critical in both clones, with only the fourth glycan of 15F3 being superfluous for binding. A full concentration series was performed to measure the KD of 15F3-M1, revealing a modest affinity reduction (31 ± 4 nM versus 19 ± 3 nM) and a significant decrease in maximum concentration bound, compared with the parent clone. (Figure 3b, e).
The observed Fbmax values were low (< ~20%); to assess whether this was because of incompletely glycosylated aptamer, we purified the fully glycosylated 15F1 and 15F3 F-RNA by urea PAGE and repeated the nitrocellulose filter binding assay. Although glycoDNA aptamers from SELMA and natural RNA aptamers derived from our capture method exhibited excellent binding after PAGE purification,8a-c, 24 in this case, fully glycosylated 15F1 and 15F3 exhibited minimal binding signal after PAGE purification (Figure 4a). We hypothesized that the active 15F1 and 15F3 aptamers might be in kinetically trapped folding states after transcription and/or glycosylation, which convert to thermodynamically favored but inactive states upon denaturing PAGE purification and refolding.
Figure 4.

Filter binding of gel-purified 15F3 and stabilized stem variant. a) Filter binding curves for 15F3 crude, heat refolded and gel purified, and 15F3-M1-Mod gel purified. Data were obtained in duplicate. b) Long-stem mutant of 15F3-M1 predicted secondary structure. X = (A)10 spacer, Y = reverse primer (see SI Table 1).
In the case of 15F3, further inspection of the predicted fold (Figure 3d) suggested a route to stabilization of the structure. Three of the four glycans in 15F3 reside near the end of a stem or in a GNRA tetraloop (specifically GUGA), which is a common natural RNA folding motif.9c Although this fold has not to our knowledge been reported in 2′-fluoro-pyrimidine aptamers, the major hydrogen bonding interactions that confer stability to the tetraloop are all between the purines at the first, third and fourth positions, with base stacking contributing to stability between the 2-4 bases in the loop in some variations.25 Therefore, the 2′-fluoro uridine could reasonably be accommodated in the canonical GNRA structure (SI Figure 13). However, following attachment of the bulky Man9 moieties to the loop and two stem positions, the structure might be kinetically stable in selection, but not retain enough thermodynamic stability to refold to the same structure after denaturing urea-gel purification. Based on mFold26 predictions, another possible fold with similar thermodynamic stability contains a completely different stem/loop not involving any of the glycosylation sites (SI Figure 14).
To increase the stability of this potentially important stem tetraloop motif, we extended the stem (15F3-M1-Mod, Figure 4b, SI Table 5 and SI Figure 15). This modification necessitated the loss of the “non-essential” glycosylation site (see 15F3-M1). This long-stem variant was transcribed, click glycosylated, gel purified, then radiolabeled and refolded. In the nitrocellulose filter binding assay, we now observed strong binding (KD 36 ± 4 nM) after gel purification/refolding, and a significantly higher Fbmax (51%) compared to the parent clone, which displayed no binding at all after gel purification (Figure 4a). These data support our hypothesis that the active structure contains this stem-GNRA tetraloop, which is thermodynamically unstable in the original 15F3 aptamer.
It is worth noting that 15F3 and 15F3-M1-Mod, with KDs of 13 ± 2 and 36 ± 4 nM respectively, exhibit 14,000- and 5000-fold binding enhancements relative to monovalent Man9 (KD 180 μM). Moreover, this affinity enhancement is about 17–50-fold greater than that achieved by unstructured glycan clusters of comparable multivalency, such as the trivalent Man9 dendrimer described by Wong.27a
In summary, we have devised Capture SELMA, a selection method for evolving glycan-modified 2′-fluoro-RNA carbohydrate cluster ligands capable of presenting oligomannose Man9 glycans in a cluster that leads to very tight (mid- to low- nanomolar KD) binding for the carbohydrate-binding antibody 2G12. This selection method is applicable to the discovery of F-RNA aptamers containing other modifications, appropriate for binding to diverse targets. Further studies along these lines will be reported in due course.
Supplementary Material
ACKNOWLEDGMENT
This work was supported by NIH grants R01-AI113737 and R01-AI090745. We are also grateful to Drs. Satoru Horiya, Iain MacPherson, and J. Sebastian Temme for helpful discussions.
ABBREVIATIONS
- CBPs
carbohydrate binding proteins
- HIV
Human immunodeficiency virus
- CuAAC
Copper(I)-catalyzed azide/alkyne cycloaddition
- KD
equilibrium dissociation constant
- PAGE
polyacrylamide gel electrophoresis
Footnotes
Supporting Information. List of synthetic oligonucleotides used, methods, supplementary binding data, supporting figures and tables, and supporting references. This material is available free of charge via the Internet at http://pubs.acs.org.”
REFERENCES
- 1.Glycan-Binding Proteins. In Essentials of Glycobiology, 3rd ed.; Varki AC, Richard D; Esko Jeffrey D., et al. , Ed. Cold Spring Harbor Laboratory Press: Cold Spring Harbor (NY), 2015–2017. https://www.ncbi.nlm.nih.gov/books/NBK453036/ (accessed on 5/9/2021). [Google Scholar]
- 2.(a) Heimburg-Molinaro J; Lum M; Vijay G; Jain M; Almogren A; Rittenhouse-Olson K, Cancer vaccines and carbohydrate epitopes. Vaccine 2011, 29 (48), 8802–26; [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Astronomo RD; Burton DR, Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat. Rev. Drug Discov 2010, 9 (4), 308–24; [DOI] [PMC free article] [PubMed] [Google Scholar]; (c) Horiya S; MacPherson IS; Krauss IJ, Recent strategies targeting HIV glycans in vaccine design. Nat. Chem. Biol 2014, 10 (12), 990–999; [DOI] [PMC free article] [PubMed] [Google Scholar]; (d) Bastida I; Fernández-Tejada A, Synthetic carbohydrate-based HIV-1 vaccines. Drug Discov. Today Technol 2020, 35-36, 45–56. [DOI] [PubMed] [Google Scholar]
- 3.(a) van Kooyk Y; Rabinovich GA, Protein-glycan interactions in the control of innate and adaptive immune responses. Nat. Immunol 2008, 9 (6), 593–601; [DOI] [PubMed] [Google Scholar]; (b) Johnson JL; Jones MB; Ryan SO; Cobb BA, The regulatory power of glycans and their binding partners in immunity. Trends Immunol 2013, 34 (6), 290–298; [DOI] [PMC free article] [PubMed] [Google Scholar]; (c) Marth JD; Grewal PK, Mammalian glycosylation in immunity. Nat. Rev. Immunol 2008, 8 (11), 874–887; [DOI] [PMC free article] [PubMed] [Google Scholar]; (d) Schnaar RL, Glycans and glycan-binding proteins in immune regulation: A concise introduction to glycobiology for the allergist. J. Allergy Clin. Immunol 2015, 135 (3), 609–615. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Hu M; Lan Y; Lu A; Ma X; Zhang L, Chapter One - Glycan-based biomarkers for diagnosis of cancers and other diseases: Past, present, and future. In Progress in Molecular Biology and Translational Science, Zhang L, Ed. Academic Press: 2019; Vol. 162, pp 1–24. [DOI] [PubMed] [Google Scholar]
- 5.(a) Sharon N, Carbohydrates as future anti-adhesion drugs for infectious diseases. Biochim Biophys Acta 2006, 1760 (4), 527–37; [DOI] [PubMed] [Google Scholar]; (b) Krishnamurthy VR; Sardar MYR; Ying Y; Song X; Haller C; Dai E; Wang X; Hanjaya-Putra D; Sun L; Morikis V; Simon SI; Woods RJ; Cummings RD; Chaikof EL, Glycopeptide analogues of PSGL-1 inhibit P-selectin in vitro and in vivo. Nat. Commun 2015, 6 (1), 6387; [DOI] [PMC free article] [PubMed] [Google Scholar]; (c) Zhang W; Chang KH; Basyal M; Jia Y; Ostermann LB; Fogler WE; Magnani JL; Zal MA; Zal T; Andreeff M, Combined Blockage of E-Selectin and CXCR4 (GMI-1359) Enhances Anti-Leukemia Effect of FLT3 Inhibition (Sorafenib) and Protects Hematopoiesis in Pre-Clinical AML Models. Blood 2020, 136 (Supplement 1), 17–18. [Google Scholar]
- 6.(a) Roy R; Murphy PV; Gabius H-J, Multivalent Carbohydrate-Lectin Interactions: How Synthetic Chemistry Enables Insights into Nanometric Recognition. Molecules 2016, 21 (5), 629; [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Dam TK; Brewer CF, Chapter 5 - Multivalent Lectin—Carbohydrate Interactions: Energetics and Mechanisms of Binding. In Advances in Carbohydrate Chemistry and Biochemistry, Horton D, Ed. Academic Press: 2010; Vol. 63, pp 139–164; [DOI] [PubMed] [Google Scholar]; (c) Wittmann V; Pieters RJ, Bridging lectin binding sites by multivalent carbohydrates. Chem. Soc. Rev 2013, 42 (10), 4492–4503; [DOI] [PubMed] [Google Scholar]; (d) Wittmann V, Structural investigation of multivalent carbohydrate-protein interactions using synthetic biomolecules. Curr. Opin. Chem. Biol 2013, 17 (6), 982–989; [DOI] [PubMed] [Google Scholar]; (e) Mahon E; Barboiu M, Synthetic multivalency for biological applications. Org. Biomol. Chem 2015, 13 (43), 10590–10599; [DOI] [PubMed] [Google Scholar]; (f) Yeldell SB; Seitz O, Nucleic acid constructs for the interrogation of multivalent protein interactions. Chem. Soc. Rev 2020, 49 (19), 6848–6865; [DOI] [PubMed] [Google Scholar]; (g) Ahmad KM; Xiao Y; Tom Soh H, Selection is more intelligent than design: Improving the affinity of a bivalent ligand through directed evolution. Nucleic Acids Res 2012, 40 (22), 11777–11783; [DOI] [PMC free article] [PubMed] [Google Scholar]; (h) Guo C; Watkins CP; Hili R, Sequence-Defined Scaffolding of Peptides on Nucleic Acid Polymers. J. Am. Chem. Soc 2015, 137 (34), 11191–11196. [DOI] [PubMed] [Google Scholar]
- 7.(a) Tuerk C; Gold L, Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249 (4968), 505–10; [DOI] [PubMed] [Google Scholar]; (b) Zhou J; Rossi J, Aptamers as targeted therapeutics: Current potential and challenges. Nat. Rev. Drug Discov 2017, 16 (3), 181–202. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.(a) MacPherson IS; Temme JS; Habeshian S; Felczak K; Pankiewicz K; Hedstrom L; Krauss IJ, Multivalent Glycocluster Design through Directed Evolution. Angew. Chem. Int. Ed 2011, 50 (47), 11238–11242; [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Temme JS; Drzyzga MG; MacPherson IS; Krauss IJ, Directed Evolution of 2G12-Targeted Nonamannose Glycoclusters by SELMA. Chem. Eur. J 2013, 19 (51), 17291–17295; [DOI] [PMC free article] [PubMed] [Google Scholar]; (c) Temme JS; MacPherson IS; DeCourcey JF; Krauss IJ, High Temperature SELMA: Evolution of DNA-Supported Oligomannose Clusters Which Are Tightly Recognized by HIV bnAb 2G12. J. Am. Chem. Soc 2014, 136 (5), 1726–1729; [DOI] [PMC free article] [PubMed] [Google Scholar]; (d) Horiya S; Bailey JK; Krauss IJ, Chapter Four - Directed Evolution of Glycopeptides Using mRNA Display. In Methods Enzymol, Imperiali B, Ed. Academic Press: 2017; Vol. 597, pp 83–141; [DOI] [PMC free article] [PubMed] [Google Scholar]; (e) Temme JS; Krauss IJ, SELMA: Selection with Modified Aptamers. Curr. Protoc. Chem. Biol 2015, 7 (2), 73–92; [DOI] [PMC free article] [PubMed] [Google Scholar]; (f) Horiya S; Bailey JK; Temme JS; Guillen Schlippe YV; Krauss IJ, Directed Evolution of Multivalent Glycopeptides Tightly Recognized by HIV Antibody 2G12. J. Am. Chem. Soc 2014, 136 (14), 5407–5415. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.(a) Piao X; Wang H; Binzel DW; Guo P, Assessment and comparison of thermal stability of phosphorothioate-DNA, DNA, RNA, 2′-F RNA, and LNA in the context of Phi29 pRNA 3WJ. RNA 2018, 24 (1), 67–76; [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Ostergaard ME; Dwight T; Berdeja A; Swayze EE; Jung ME; Seth PP, Comparison of duplex stabilizing properties of 2′-fluorinated nucleic acid analogues with furanose and non-furanose sugar rings. J. Org. Chem 2014, 79 (18), 8877–81; [DOI] [PubMed] [Google Scholar]; (c) Batey RT; Rambo RP; Doudna JA, Tertiary Motifs in RNA Structure and Folding. Angew. Chem. Int. Ed 1999, 38 (16), 2326–2343; [DOI] [PubMed] [Google Scholar]; (d) Forconi M; P. Schwans Jason; Porecha Rishi H.; Sengupta Raghuvir N.; Piccirilli Joseph A.; Herschlag D, 2′-Fluoro Substituents Can Mimic Native 2′-Hydroxyls within Structured RNA. Chem. Biol 2011, 18 (8), 949–954; [DOI] [PMC free article] [PubMed] [Google Scholar]; (e) Butcher SE; Pyle AM, The Molecular Interactions That Stabilize RNA Tertiary Structure: RNA Motifs, Patterns, and Networks. Acc. Chem. Res 2011, 44 (12), 1302–1311. [DOI] [PubMed] [Google Scholar]
- 10.(a) Cummins LL; Owens SR; Risen LM; Lesnik EA; Freier SM; McGee D; Guinosso CJ; Cook PD, Characterization of fully 2′-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity. Nucleic Acids Res 1995, 23 (11), 2019–2024; [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Pieken WA; Olsen DB; Benseler F; Aurup H; Eckstein F, Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes. Science 1991, 253 (5017), 314–7; [DOI] [PubMed] [Google Scholar]; (c) Li Y; Breaker RR, Kinetics of RNA Degradation by Specific Base Catalysis of Transesterification Involving the 2′-Hydroxyl Group. J. Am. Chem. Soc 1999, 121 (23), 5364–5372; [Google Scholar]; (d) Duffy K; Arangundy-Franklin S; Holliger P, Modified nucleic acids: replication, evolution, and next-generation therapeutics. BMC Biology 2020, 18 (1), 112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Trkola A; Purtscher M; Muster T; Ballaun C; Buchacher A; Sullivan N; Srinivasan K; Sodroski J; Moore JP; Katinger H, Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol 1996, 70 (2), 1100–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.(a) Seabright GE; Cottrell CA; van Gils MJ; D’Addabbo A; Harvey DJ; Behrens A-J; Allen JD; Watanabe Y; Scaringi N; Polveroni TM; Maker A; Vasiljevic S; de Val N; Sanders RW; Ward AB; Crispin M, Networks of HIV-1 Envelope Glycans Maintain Antibody Epitopes in the Face of Glycan Additions and Deletions. Structure 2020, 28 (8), 897–909.e6; [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Calarese DA; Scanlan CN; Zwick MB; Deechongkit S; Mimura Y; Kunert R; Zhu P; Wormald MR; Stanfield RL; Roux KH; Kelly JW; Rudd PM; Dwek RA; Katinger H; Burton DR; Wilson IA, Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003, 300 (5628), 2065–2071. [DOI] [PubMed] [Google Scholar]
- 13.(a) Thirunavukarasu D; Chen T; Liu Z; Hongdilokkul N; Romesberg FE, Selection of 2′-Fluoro-Modified Aptamers with Optimized Properties. J. Am. Chem. Soc 2017, 139 (8), 2892–2895; [DOI] [PubMed] [Google Scholar]; (b) Pfeiffer F; Tolle F; Rosenthal M; Brandle GM; Ewers J; Mayer G, Identification and characterization of nucleobase-modified aptamers by click-SELEX. Nat. Protoc 2018, 13 (5), 1153–1180; [DOI] [PubMed] [Google Scholar]; (c) Tolle F; Brändle GM; Matzner D; Mayer G, A Versatile Approach Towards Nucleobase-Modified Aptamers. Angew. Chem. Int. Ed 2015, 54 (37), 10971–10974; [DOI] [PubMed] [Google Scholar]; (d) Rohloff JC; Gelinas AD; Jarvis TC; Ochsner UA; Schneider DJ; Gold L; Janjic N, Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents. Mol. Ther. Nucleic Acids 2014, 3, e201. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.(a) Dunn MR; McCloskey CM; Buckley P; Rhea K; Chaput JC, Generating Biologically Stable TNA Aptamers that Function with High Affinity and Thermal Stability. J. Am. Chem. Soc 2020. 142 (17), 7721–7724; [DOI] [PubMed] [Google Scholar]; (b) Renders M; Miller E; Hollenstein M; Perrin D, A method for selecting modified DNAzymes without the use of modified DNA as a template in PCR. Chem. Comm 2015, 51 (7), 1360–1362; [DOI] [PubMed] [Google Scholar]; (c) Gordon CKL; Wu D; Pusuluri A; Feagin TA; Csordas AT; Eisenstein MS; Hawker CJ; Niu J; Soh HT, Click-Particle Display for Base-Modified Aptamer Discovery. ACS Chem. Biol 2019, 14 (12), 2652–2662. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Sousa R; Padilla R, A mutant T7 RNA polymerase as a DNA polymerase. EMBO J 1995, 14 (18), 4609–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Tanasova M; Goeldi S; Meyer F; Hanawalt PC; Spivak G; Sturla SJ, Altered minor-groove hydrogen bonds in DNA block transcription elongation by T7 RNA polymerase. Chembiochem 2015, 16 (8), 1212–1218. [DOI] [PubMed] [Google Scholar]
- 17.Rostovtsev VV; Green LG; Fokin VV; Sharpless KB, A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective “Ligation” of Azides and Terminal Alkynes. Angew. Chem. Int. Ed 2002, 41 (14), 2596–2599. [DOI] [PubMed] [Google Scholar]
- 18.(a) Bachem G; Wamhoff E-C; Silberreis K; Kim D; Baukmann H; Fuchsberger F; Dernedde J; Rademacher C; Seitz O, Rational Design of a DNA-Scaffolded High-Affinity Binder for Langerin. Angew. Chem. Int. Ed 2020, 59 (47), 21016–21022; [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Novoa A; Winssinger N, DNA display of glycoconjugates to emulate oligomeric interactions of glycans. Beilstein J. Org. Chem 2015, 11, 707–719; [DOI] [PMC free article] [PubMed] [Google Scholar]; (c) Gierlich J; Gutsmiedl K; Gramlich PME; Schmidt A; Burley GA; Carell T, Synthesis of Highly Modified DNA by a Combination of PCR with Alkyne-Bearing Triphosphates and Click Chemistry. Chem. Eur. J 2007, 13 (34), 9486–9494. [DOI] [PubMed] [Google Scholar]
- 19.Zhu B; Hernandez A; Tan M; Wollenhaupt J; Tabor S; Richardson CC, Synthesis of 2′-Fluoro RNA by Syn5 RNA polymerase. Nucleic Acids Res 2015, 43 (14), e94. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.(a) Huppert JL, Structure, location and interactions of G-quadruplexes. FEBS J 2010, 277 (17), 3452–8; [DOI] [PubMed] [Google Scholar]; (b) Bochman ML; Paeschke K; Zakian VA, DNA secondary structures: stability and function of G-quadruplex structures. Nat. Rev. Genet 2012, 13 (11), 770–80. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.A selection was attempted prior to optimization of this sequence, which failed to yield strong enrichment or tight binders.
- 22.Rio DC, Filter-Binding Assay for Analysis of RNA–Protein Interactions. Cold Spring Harb. Protoc 2012, 2012 (10), pdb.prot071449. [DOI] [PubMed] [Google Scholar]
- 23.Lorenz R; Bernhart SH; Honer Zu Siederdissen C; Tafer H; Flamm C; Stadler PF; Hofacker IL, ViennaRNA Package 2.0. Algorithms Mol. Biol 2011, 6 (1), 26. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.MacPherson IS; Temme JS; Krauss IJ, DNA display of folded RNA libraries enabling RNA-SELEX without reverse transcription. Chem. Comm 2017, 53 (19), 2878–2881. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.(a) Cheong H-K; Kim N-K; Cheong C, RNA Structure: Tetraloops. In eLS, 2015; pp 1–6; [Google Scholar]; (b) Richardson KE; Adams MS; Kirkpatrick CC; Gohara DW; Znosko BM, Identification and Characterization of New RNA Tetraloop Sequence Families. Biochemistry 2019, 58 (48), 4809–4820; [DOI] [PMC free article] [PubMed] [Google Scholar]; (c) Correll CC; Swinger K, Common and distinctive features of GNRA tetraloops based on a GUAA tetraloop structure at 1.4 A resolution. RNA 2003, 9 (3), 355–363. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Zuker M, Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 2003, 31 (13), 3406–3415. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.(a) Wang S-K; Liang P-H; Astronomo RD; Hsu T-L; Hsieh S-L; Burton DR; Wong C-H, Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. PNAS 2008, 105 (10), 3690; [DOI] [PMC free article] [PubMed] [Google Scholar]; For other examples of rationally-designed oligomannose clusters, see: ; (b) Li H; Wang L-X, Design and synthesis of a template-assembled oligomannose cluster as an epitope mimic for human HIV-neutralizing antibody 2G12. Org. Biomol. Chem 2004, 2 (4), 483–488; [DOI] [PubMed] [Google Scholar]; (c) Wang L-X; Ni J; Singh S; Li H, Binding of High-Mannose-Type Oligosaccharides and Synthetic Oligomannose Clusters to Human Antibody 2G12: Implications for HIV-1 Vaccine Design. Chem. Biol 2004, 11 (1), 127–134; [DOI] [PubMed] [Google Scholar]; (d) Ni J; Song H; Wang Y; Stamatos NM; Wang L-X, Toward a Carbohydrate-Based HIV-1 Vaccine: Synthesis and Immunological Studies of Oligomannose-Containing Glycoconjugates. Bioconjug. Chem 2006, 17 (2), 493–500; [DOI] [PubMed] [Google Scholar]; (e) Krauss IJ; Joyce JG; Finnefrock AC; Song HC; Dudkin VY; Geng X; Warren JD; Chastain M; Shiver JW; Danishefsky SJ, Fully Synthetic Carbohydrate HIV Antigens Designed on the Logic of the 2G12 Antibody. J. Am. Chem. Soc 2007, 129 (36), 11042–11044; [DOI] [PubMed] [Google Scholar]; (f) Wang J; Li H; Zou G; Wang L-X, Novel template-assembled oligosaccharide clusters as epitope mimics for HIV-neutralizing antibody 2G12. Design, synthesis, and antibody binding study. Org. Biomol. Chem 2007, 5 (10), 1529–1540; [DOI] [PubMed] [Google Scholar]; (g) Gorska K; Huang K-T; Chaloin O; Winssinger N, DNA-Templated Homo- and Heterodimerization of Peptide Nucleic Acid Encoded Oligosaccharides that Mimick the Carbohydrate Epitope of HIV. Angew. Chem. Int. Ed 2009, 48 (41), 7695–7700; [DOI] [PubMed] [Google Scholar]; (h) Ciobanu M; Huang K-T; Daguer J-P; Barluenga S; Chaloin O; Schaeffer E; Mueller CG; Mitchell DA; Winssinger N, Selection of a synthetic glycan oligomer from a library of DNA-templated fragments against DC-SIGN and inhibition of HIV gp120 binding to dendritic cells. Chem. Comm 2011, 47 (33), 9321–9323; [DOI] [PubMed] [Google Scholar]; (i) Marradi M; Di Gianvincenzo P; Enríquez-Navas PM; Martínez-Ávila OM; Chiodo F; Yuste E; Angulo J; Penadés S, Gold Nanoparticles Coated with Oligomannosides of HIV-1 Glycoprotein gp120 Mimic the Carbohydrate Epitope of Antibody 2G12. J. Mol. Biol 2011, 410 (5), 798–810. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
